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Poster Session-I 89HCoV infection developed LRI. BAL was performed in 38 (18%)
patients, 6 of whom had HRhV detection in upper respiratory sam-
ples. Two of these BALs tested positive for HRhV.
Conclusion:This prospective study is the first to describe the nat-
ural history of HCoV and HRhV infections during the first 100 days
after HCT. HRhV and HCoV infections were common and pro-
longed shedding may occur. While HRhV frequently caused symp-
tomatic URI and occasionally LRI, there was no apparent
association with either URI or LRI in patients infected with
HCoV in this study group. However, this study does not exclude
the possibility that HCoV is a rare cause of lower tract disease. Stud-
ies are on-going to further investigate this.244
TACROLIMUS AND SIROLIMUS AS GVHD PROPHYLAXIS FOR SIBLING DO-
NOR HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) USING THREE
CONDITIONING REGIMENS; FLUDARABINE-MELPHALAN, FTBI-VP16,
AND BUSULFAN-CYCLOPHOSPHAMIDE
Nakamura, R.1, Rodriguez, R.1, Palmer, J.2, Parker, P.1,
Nademanee, A.1, Shayani, S.3, Smith, E.1, Karanes, C.1, Snyder, D.1,
O’Donnell, M.1, Krishnan, A.1, Pullarkat, V.1, Senitzer, D.1,
Rosenthal, J.4, Kogut, N.1, Forman, S.J.1 1City of Hope National Medical
Center, Duarte, CA; 2City of HopeNationalMedical Center, Duarte, CA;
3City of Hope National Medical Center, Duarte, CA; 4City of Hope
National Medical Center, Duarte, CA
Based on encouraging phase II data, we prospectively tested the
combination of tacrolimus and sirolimus (tacro/siro) as GVHD pro-
phylaxis in patients undergoing HLA-matched sibling donor HCT.
Eighty-five patients were stratified according to conditioning regi-
men as follows: fludarabine-melphalan (FluMel: n 5 46); FTBI-
VP16 (TBI: n 5 28), and busulfan-cyclophosphamide (BuCy: n 5
11).Themedian agewas 47 years (range: 10–67).The patient diagno-
ses were AML (33), ALL (18), NHL/HD (11/3), MDS (6), CML (5),
myeloma (3), MPD (3), and CLL (1). A majority of patients received
a PBSC graft except for five who received a BM graft with the overall
median CD341 cell dose of 5.1  106/kg (range: 1.7–10.5). All pa-
tients engrafted (median neutrophil engraftment: 15 days). Fifty
five of 85 patients are alive after a median follow up of 26 months
(range: 14–37). Twenty-two patients died of relapse while eight
were due to non-relapse causes including acute/chronic GVHD (3),
multi-organ failure (1), mucormycosis (1), leukoencephalopathy (1),
and respiratory failure (1). The probabilities of overall survival
(OS), disease-free survival (DFS), and relapse at 2 years were 66%
(CI: 59–72), 58% (CI: 52–64), and 34% (CI: 28–42), respectively.
The day 100 and 2 year transplant-related mortality (TRM) was
3.6% (CI: 2–12) and 10.2% (CI: 7–20), respectively. Conditioning
regimen was not significantly associated with OS, DFS, relapse, or
TRM. The cumulative incidence of acute GVHD grade II-IV and
III-IVwas 40% (CI: 37–50) and 16% (CI: 12–27), respectively. Four-
teen of 21 patients with grade II GVHD had upper GI involvement
only. There was a trend for higher probability of acute GVHD in pa-
tients conditioned with BuCy compared with TBI and FluMel (64%,
49% and 34%, respectively)(p 5 0.12). The probability of chronic
GVHD was 45% (limited: 14%, extensive: 31%). Thrombotic mi-
croangiopathy (TMA) was a major complication which developed
in 19% of patients, significantly associated with BuCy (55%) com-
pared with TBI (25%) and FluMel (6.5%)(p5 0.005). TMA was re-
versible in all cases, managed by holding tacro and/or siro except for
two who required plasma exchange/hemodialysis. In summary, the
combination of tacro/siro is associated with a low TRM rate over 2
years. The encouraging results on acute GVHD in our study support
the ongoing phase III trial comparing tacro/siro versus tacro/MTX
(CTN 0402). However, TMA was frequently observed and the risk
was significantly greater with BuCy conditioning.245
PREDICTION OF VOD USING BIOMARKERS OF ENDOTHELIAL INJURY
Cutler, C.1, Aldridge, J.2, Kim, H.T.2, Ayanian, S.3, Bradwin, G.3,
Revta, C.1, Murga, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1, Armand, P.1,
Richardson, P.G.1, Soiffer, R.1, Ritz, J.1, Antin, J.H.1 1Dana-Farber
Cancer Institute, Boston, MA; 2Dana-Farber Cancer Institute, Boston,
MA; 3Children’s Hospital, Boston, MAClinical risk factors for VOD are well known, however, predicting
the occurrence of VOD in individuals remains challenging. Since the
primary mechanism of injury in VOD is conditioning-related dam-
age to hepatic sinusoidal endothelial cells and hepatocytes, we mea-
sured soluble biomarkers of endothelial injury in the peri-stem cell
transplant (SCT) period to determine if they correlated with the oc-
currence of VOD.
Methods: 59 patients who underwent HLA-matched donor SCT
received conditioning with cyclophosphamide (1800 mg/m2 x 2) and
TBI (14 Gy) and tacrolimus with sirolimus or methotrexate as
GVHD prophylaxis are included in this analysis. They are stratified
based on the occurrence of VOD (VOD1 n 5 18, VOD- n 5 41),
diagnosed by clinical, radiologic and pathologic criteria. Banked
samples collected after conditioning but prior to SCT (day -1) and
weekly after SCT (day 7, 14, 21) were thawed and analyzed using
commercial ELISA kits and quantified using a VersaMax plate
reader. Von Willebrand Factor (vWF) and thrombomodulin (TM)
were assayed in plasma; E-selectin and soluble intercellular adhesion
molecule-1 (ICAM) were assayed in serum. Assays were performed
in duplicate and the mean of two assays were analyzed. Not all pa-
tients had every time point analyzed due to missing specimens.
The within-sample results were compared using the 2-sided Wil-
coxon rank-sum test using the Bonferroni method to adjust for mul-
tiple comparisons.
Results: Among patients who received sirolimus, levels of vWF,
TM and ICAM were significantly different between VOD1 and
VOD- groups on day -1 (p # 0.04), day17 (p # 0.0001) and
day114 (p # 0.004). E-selectin was only predictive on day17 (p 5
0.009). Using pre-defined thresholds, vWF (.1400 IU/ml) and
TM (.100 ng/ml) levels on day 17 were 100% sensitive and
100% specific in predicting the occurrence of VOD. Biomarkers
could not reliably predict VOD among patients not treated with si-
rolimus. There were no differences in biomarkers among VOD- pa-
tients, suggesting that in the absence of VOD,markers of endothelial
injury are not elevated, even when sirolimus is used.
Conclusions: Plasma vWF and TM and serum ICAM elevations
before and early after SCT can be used to predict the occurrence of
VOD in patients receiving sirolimus. This analysis demonstrates the
contribution of sirolimus to endothelial injury and VOD after SCT,
and may help select patients in whom prophylactic or pre-emptive
strategies against endothelial damage and VOD may be useful.246
CYTOMEGALOVIRUS (CMV) REACTIVATION IN RECIPIENTS OF UMBILI-
CAL CORD BLOOD (UCB): RISK FACTORS AND OUTCOMES
Beck, J.C.1, DeFor, T.E.1, Brunstein, C.G.2, Weisdorf, D.J.2,
Wagner, J.E.1, Verneris, M.R.1 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
Pre-transplant CMV serostatus has been shown to be an adverse
risk factor in allo-HCT recipients. The consequences of CMV reac-
tivation after transplantation have not been extensively described in
theUCB setting.We analyzed the impact of pre-transplant CMV se-
ropositivity and CMV reactivation on UCBT outcomes. Between
1994 and 2007, 332 patients with malignancies underwent UCBT
at the University of Minnesota and 54% were CMV seropositive.
AllUCBunits were considered seronegative.While there was a trend
to greater day 100 TRM (p5 0.07), CMV seropositivity was not as-
sociated with survival (p 5 0.55) or relapse (p 5 0.78). For the 180
CMV seropositive patients, the median age at UCBT was 51 years
(range 6–68). Myeloablative conditioning consisting of cyclophos-
phamide (CY) and TBI 13.2 Gy, with ATG (n5 31, 25%) or fludar-
abine (FLU, n5 91, 75%).Myeloablative conditioning was followed
by single (n 5 56, 46%) or double (n 5 66, 54%) UCBT. Reduced
intensity conditioning (RIC) consisted of CY, FLU and TBI 2 Gy
and was followed by double UCBT in all 58 patients. GVHD pro-
phylaxis consisted of cyclosporine/methylprednisone (17%) or cy-
closporine/mycophenolate mofetil (83%). All patients had weekly
screening for CMV reactivation (by pp65 antigenemia or PCR)
and received acyclovir prophylaxis until day 100. The incidence of
CMV reactivation was 51% (92/180) with no difference in recipients
of a myeloablative vs. RIC (p 5 0.33). Among recipients of myeloa-
blative conditioning, CMV reactivation was similar regardless of
GVHD prophylaxis regimen (p 5 0.8). In univariate analysis, the
only variables associated with CMV reactivation were older age
90 Poster Session-I(p 5 0.04) and higher HLA disparity (p 5 0.04). Variables not
associated with CMV reactivation were gender, disease risk
(standard vs. high), conditioning regimen, and cell doses defined as
total nucleated, CD34 or CD3 cell dose. No factor was associated
with CMV reactivation in multivariate analysis. CMV reactivation
did not impact incidence of TRM (p 5 0.88), relapse (p 5 0.62) or
survival (p 5 0.78). Likewise, CMV reactivation was not associated
with risk of acute or chronic GVHD. In summary, this analysis,
the largest study to date on CMV reactivation in UCBT patients,
suggests that CMV reactivation is similar to that reported for other
HSC sources and has little demonstrable impact on transplant out-
comes. Perhaps, current CMV prophylaxis and treatment strategies
have marginalized the historical significance of CMV in recipients of
allogeneic HSC.247
PALIFERMIN FOR PREVENTION OF ORAL MUCOSITIS (OM) IN ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) USING A FRAC-
TIONATED TOTAL BODY IRRADIATION (FTBI)-BASED CONDITIONING
REGIMEN
Shayani, S.1, Spielberger, R.T.2, Tsai, N.-C.3, Palmer, J.3, Chau, S.1,
Forman, S.J.2 1City of Hope; 2City of Hope; 3City of Hope, Duarte, CA
OM is a complication of myeloablative therapy followed by
HSCT. Severe OM in patients (pts) undergoing HSCT with
a FTBI-based conditioning regimen has been reported in up to
80% of pts (Woo et al. Cancer 1993; 72). Palifermin, (PAL, Kepiv-
ance), a recombinant human keratinocyte growth factor, has been
shown to reduce the duration and severity of OM in pts undergoing
FTBI-based conditioning regimen prior to autologous HSCT
(Spielberger et al. NEJM 2004; 351). Benefits of PAL in pts under-
going allogeneic (Allo) HSCT from a related or a matched unrelated
donor were evaluated in a comparative, retrospective study. Data on
a cohort of pts who received PAL (N 5 33) were compared to a co-
hort of pts who did not (Control: N 5 31). Conditioning regimen
consisted of FTBI and etoposide. OM was defined as ‘‘Mild’’ and
‘‘Severe’’ based on CTC v2.0 (Mild 5 grades 1 and 2, Severe 5
grades 3 and 4). Baseline characteristics for both cohorts were not
statistically different in respect to gender, diagnosis, disease status,
GVHD prophylaxis regimen, type of donor, and stem cell source.
Median age was lower for pts in the control group (44 vs. 34 years,
P 5 0.01). All pts developed OM with a median duration of 15
days for the PAL cohort and 20 days for the control (P5 0.05). Over-
all incidence of severe OM by univariate analysis was 55% and 81%
for pts in the PAL and control groups, respectively (P 5 0.03). Me-
dian duration of severe OM among all pts was 2 days (0–28) for those
who received PAL and 5 days (0–16) for pts who did not (P5 0.007).
Patients in the PAL group received intensive oral care (delivered by
certified respiratory therapists) for 11 days (0–30) vs. 15 days (0–47)
for pts in the control group (P5 0.02). Median opioid analgesic use
attributed to mucositis pain (in morphine equivalents) was 542 (47–
6330) mg and 837 (225–18137) mg for PAL and control groups (P5
0.14). Cumulative incidence of acute GVHD grades III and IV was
9% for pts in PAL group and 29% for the control (P5 0.05). Overall
probability of 100-day survival for PAL and control cohorts was
93.9% and 77.4% (P 5 0.06). No clinically significant differences
were observed in duration of TPN use, length of hospital stay, or
ICU admissions. When compared, use of methotrexate did not im-
pact the outcomes.
Conclusions: Results suggests that PAL reduced the incidence of
severe OM and the duration of all grades of OM, as well as reducing
the health resource utilization for prevention and treatment of OM
in pts undergoing Allo HSCT.248
COST ANALYSIS OF MOBILIZATION AND AUTOLGOUS TRANSPLANTA-
TION IN PATIENTSWHORECEIVED AMD3100 AFTER FAILING STANDARD
MOBILIZATION
Delgado, E.1, LeMaistre, C.F.1, Bachier, C.1, Smith, B.2, Lopez-
Gonzalez, G.1, Hougham, M.1, Kaleel, S.1, Shaughnessy, P.1 1Texas
Transplant Institute, San Antonio, TX; 2Altarum, San Antonio, TX
This retrospective study evaluated the difference in clinical out-
comes and costs of mobilization and transplant between pts whoachieved sufficient CD341 cells to proceed to transplant using
a standard mobilization regimen (control group) versus pts who
had failed previous mobilization regimens and were remobilized
with AMD3100 and G-CSF in the compassionate use protocol
(CUP). A total of 88 pts in the control group and 36 pts in CUP
were evaluated. Following AMD3100 administration, 33 (94%) pts
achieved successful mobilization of .2 million/kg CD341 cells. A
median of 3.36 106 CD341 cells/kg (range, 0.51–13.05) were col-
lected in a median of 3 (range, 1–4) apheresis days. In comparison,
control pts collected a median of 10.8 106 CD341 cells/kg (range,
1.95–69.32) in a median of 2 (range, 1–6) apheresis days. Twenty-
eight CUP pts went on to transplant and had a median day to
ANC . 500/ml of 11 days (range, 9–17) and platelets .20,000 /ml
of 27 days (range, 13–37). At day 100, 92% of the CUP pts reached
engraftment and there were no transplant related mortalities. The
control population had a median day to ANC .500/ul of 11 days
(range, 8–14) and platelets .20,000/ml of 18 days (range, 9–83).
The control group experienced 100% engraftment and one trans-
plant related fatality. Relapse occurred in 14% of the CUP pts and
32 % of the control pts. The median cost of remobilization with
AMD3100 was $2,959 less in the CUP pts than the median cost of
initial mobilization for the control group, but this was not signifi-
cantly different between the groups. The median total cost of mobi-
lization in the CUP pts, including initial mobilization costs, was
$16,927 more than in the control pts (p\0.0001). In both groups
of pts greater than 95% of total transplant costs occurred in the first
30 days of the transplant course. The difference in the total median
transplant costs at day 30 in the CUPpts was $7,373more than in the
control pts. (p 5 0.0024). CUP pts incurred 91% of total costs and
control pts 57% of total costs in the first 30 days. In conclusion, re-
mobilization with AMD31001G-CSF allowed a high percentage of
patients who failed standard mobilization to subsequently mobilize
adequate CD341 cells and proceed to autologous transplant with
acceptable clinical outcomes. Pts who required remobilization also
had an increased cost of transplantation because of increased inpa-
tient costs.249
HIGHER COSTS OF UMBILICAL CORD BLOOD (UCB) TRANSPLANTATION
COMPARED TO HEMATOPOIETIC CELL TRANSPLANTATION (HCT) USING
MATCHED RELATED DONORS (MRD): INFLUENCE OF ENGRAFTMENT
AND POST-HCT COMPLICATIONS
Majhail, N.S., Mothukuri, J.M., Brunstein, C.G., Weisdorf, D.J. Uni-
versity of Minnesota, Minneapolis, MN
Allogeneic HCT is a complex, resource intense and costly proce-
dure. UCB is an alternative graft source for patients without MRD;
however, costs of UCB HCT have not been described. We com-
pared the costs of HCT within the first 100 days among consecutive
adult patients (age$18 years) who receivedMRD (N5 130) orUCB
(N 5 164) HCT from 2004–2006. Patients received either myeloa-
blative (MA; MRD 5 67, UCB 5 63) or non-myeloablative (NMA;
MRD5 54, UCB5 110) conditioning. The four groups were com-
parable except for a higher proportion of young (age# 50 years) re-
cipients among MA regimens and HLA mismatched grafts among
UCB recipients. Cumulative incidence of graft failure was signifi-
cantly higher among UCB recipients (MA MRD 3%, MA UCB
19%, NMA MRD 0%, NMA UCB 8% [p\ 0.01]), as was the me-
dian time to neutrophil engraftment (17 days, 23 days, 7 days, 13
days [p \ 0.01]). The 100-day probabilities of overall survival
(81%, 70%, 78%, 78% [P 5 0.95]) and cumulative incidence of
TRM (21%, 29%, 20%, 19% [P 5 0.55]) were comparable. Cumu-
lative incidence of acute severeGVHDand rates of major post-HCT
complications (dialysis, mechanical ventilation and hepatic veno-oc-
clusive disease) were also similar. The median cost per day survived
(excluding costs of graft acquisition) was $1016 (interquartile range
[IQR] 796–2232) for MA MRD, $2082 (IQR 1306–6219) for MA
UCB, $612 (IQR 473–1023) for NMA MRD and $1156 (IQR
616–2472) for NMA UCB recipients, respectively (p\ 0.001). For
all groups, room-board and pharmacy services were the major con-
tributors to totals costs of HCT. In multivariate analysis adjusting
for important patient, disease and HCT related characteristics as
well as major post-HCT complications, significant predictors for
higher costs within the first 100 days after HCT were MA UCB
HCT, graft failure, need for dialysis or mechanical ventilation and
